The difference of free light chains as a predictor of kidney damage in patients with Multiple Myeloma

Autor: Melania Carlisi, Sergio Siragusa, Giuseppe Bertuglia, Salvatrice Mancuso, Nicola Serra, Emanuela Maria Pappalardo, Mariano Sardo

Publikováno v: Epidemiology, Biostatistics, and Public Health; V. 17 N. 1 (2020)
Epidemiology, Biostatistics, and Public Health; Vol. 17 No. 1 (2020)
Epidemiology Biostatistics and Public Health, Vol 1, Iss 1 (2020)

Background: Multiple myeloma (MM) is a malignant neoplasm characterized by the clonal expansion of plasma cells that can release monoclonal immunoglobulins (monoclonal component) or part of theme. Since 2001, the k and λ serum free light chains (sFL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f47666d72dacdfdc7a7fce2529dbe5f
https://doi.org/10.2427/13292

Antimicorbial prophylaxis in patients with immune thrombocytopenia treated with rituximab:a retrospective analysis

Autor: Simona Raso, Mariasanta Napolitano, Mariano Sardo, Sergio Siragusa, Melania Carlisi, Maria Francesca Mansueto, Salvatrice Mancuso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3658::59513f9cdd51e64634b71e086fe8545b
http://hdl.handle.net/10447/340037

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

Autor: Florinda Di Piazza, Antonio Russo, Angelo Davide Contrino, Simona Raso, Mariano Sardo, Marco Bono, Paolo Casimiro, Salvatrice Mancuso, Sergio Siragusa, Alessandro Perez, Marco Santoro, Vincenzo Accurso

Publikováno v: Mediterranean Journal of Hematology and Infectious Diseases, Vol 12, Iss 1 (2020)
Mediterranean Journal of Hematology and Infectious Diseases

Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc71fa222e725572e8c062ea738f69f
http://mjhid.org/index.php/mjhid/article/view/4061

Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors

Autor: Giuseppina Novo, Marco Santoro, Vincenzo Accurso, Antonio Russo, Alessandro Perez, Angelo Davide Contrino, Sergio Siragusa, Salvatrice Mancuso, Florinda Di Piazza, Mariano Sardo

Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13e81d6ba591d01434b79d2db455067
http://hdl.handle.net/10447/388111